<DOC>
	<DOCNO>NCT00173888</DOCNO>
	<brief_summary>The purpose study evaluate 1-year treatment failure rate two sequential chemotherapy regimen : weekly docetaxel plus cisplatin follow gemcitabine ; gemcitabine plus cisplatin followed weekly docetaxelã€‚</brief_summary>
	<brief_title>Docetaxel Plus Cisplatin Followed Gemcitabine Versus Gemcitabine Plus Cisplatin Followed Docetaxel Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Lung cancer lead cause cancer death men woman worldwide . Shifting trend incidence lung cancer closely follow pattern cigarette smoking , although carcinogen implicate . Despite intensive treatment past several decade , 5-year lung-cancer survival rate remain dismal 8-14 % . Chemotherapy primary therapy patient stage IIIB/IV disease , investigator believe treatment combination two agent best first-line treatment stage IV NSCLC . In late 1970s 1980s , study conduct use combination agent . Outcomes improved agent eventually incorporate clinical practice . Weekly docetaxel study combination commonly use NSCLC chemotherapeutic agent include carboplatin , navelbine , gemcitabine . These combination study first- second-line setting . Second line chemotherapy docetaxel may affect survival ( TAX 318 , 1 year survival 37 % vs. 11 % ) . However , optimal sequence chemotherapy rarely explore . Weekly docetaxel may offer good tolerability vs. 3-weekly schedule combine docetaxel cisplatin . Based upon study , choose weekly docetaxel combination cisplatin regimen . We expect regimen would effective well tolerate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologic cytologic diagnosis stage IIIB/IV NSCLC , prior chemotherapy Age &gt; 18 year &lt; 75 year WHO PS : 0,1 Unidimensional bidimensional measurable disease Neutrophils &gt; 1.5 109/l , Platelets &gt; 100 109/l , Hemoglobin &gt; 10g/dl , Total bilirubin &lt; 1.5 UNL , AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 UNL , Alkaline phosphatases &lt; 5 UNL ; except presence bone metastasis absence liver disorder Creatinine &lt; 1 UNL , creatinine clearance &gt; 60 ml/min . Life expectancy &gt; 12 week Pregnant , lactate patient Known clinical brain leptomeningeal involvement Preexisting motor sensory neurotoxicity severity &gt; grade 1 NCICCTG criterion CHF , angina arrhythmias History significant neurological psychiatric disorder Active uncontrolled infection Contraindication use corticosteroid Concurrent treatment experimental drug within 30 day prior study entry Concurrent treatment anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Combination , Chemotherapy , non-small cell lung cancer</keyword>
</DOC>